Warning: The NCBI web site requires JavaScript to function. more...
Resource use among patients with diabetes, diabetic neuropathy, or diabetes with depression.
Le TK, Able SL, Lage MJ.
Cost Eff Resour Alloc. 2006 Oct 23;4:18.
Related citations
A retrospective study on the impact of comorbid depression or anxiety on healthcare resource use and costs among diabetic neuropathy patients.
Boulanger L, Zhao Y, Bao Y, Russell MW.
BMC Health Serv Res. 2009 Jun 30;9:111.
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL, Figgitt DP.
Pharmacoeconomics. 2004;22(6):389-411. Review.
A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine.
Misurski D, Lage MJ, Fabunmi R, Boye KS.
Appl Health Econ Health Policy. 2009;7(4):245-54. doi: 10.2165/11318730-000000000-00000.
The burden of illness of hypertension and comorbid diabetes.
Eaddy MT, Shah M, Lunacsek O, Stanford RH.
Curr Med Res Opin. 2008 Sep;24(9):2501-7. Epub 2008 Jul 29.
Final Report on Carcinogens Background Document for Styrene.
National Toxicology Program.
Rep Carcinog Backgr Doc. 2008 Sep;(8-5978):i-398.
Healthcare charges and utilization associated with diabetic neuropathy: impact of Type 1 diabetes and presence of other diabetes-related complications and comorbidities.
Zhao Y, Ye W, Boye KS, Holcombe JH, Swindle R.
Diabet Med. 2009 Jan;26(1):61-9.
Prevalence of other diabetes-associated complications and comorbidities and its impact on health care charges among patients with diabetic neuropathy.
Zhao Y, Ye W, Boye KS, Holcombe JH, Hall JA, Swindle R.
J Diabetes Complications. 2010 Jan-Feb;24(1):9-19. Epub 2008 Oct 18.
Impact of antidepressant drug adherence on comorbid medication use and resource utilization.
Katon W, Cantrell CR, Sokol MC, Chiao E, Gdovin JM.
Arch Intern Med. 2005 Nov 28;165(21):2497-503.
Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.
Menzin J, Korn JR, Cohen J, Lobo F, Zhang B, Friedman M, Neumann PJ.
J Manag Care Pharm. 2010 May;16(4):264-75.
Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy.
Lage MJ, Fabunmi R, Boye KS, Misurski DA.
Adv Ther. 2009 Feb;26(2):217-29. Epub 2009 Feb 14.
Comparing clinical and economic characteristics between commercially-insured patients with diabetic neuropathy and demographically-matched diabetic controls.
Zhao Y, Ye W, Le TK, Boye KS, Holcombe JH, Swindle R.
Curr Med Res Opin. 2009 Mar;25(3):585-97.
The presence of allele D of angiotensin-converting enzyme polymorphism is associated with diabetic nephropathy in patients with less than 10 years duration of Type 2 diabetes.
Canani LH, Costa LA, Crispim D, Gonçalves Dos Santos K, Roisenberg I, Lisbôa HR, Sarturi Tres G, Maia AL, Gross JL.
Diabet Med. 2005 Sep;22(9):1167-72.
Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
Khandker RK, Kruzikas DT, McLaughlin TP.
J Manag Care Pharm. 2008 Jun;14(5):426-41.
[Comorbidity and related costs as a burden in the treatment of outpatients with depressive disorders in a primary care setting].
Sicras Mainar A, Navarro Artieda R, Rejas Gutiérrez J, Blanca Tamayo M, Serrat Tarrés J, Llopart López JR.
Farm Hosp. 2007 Mar-Apr;31(2):101-5. Spanish.
Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data.
Yu AP, Wu EQ, Birnbaum HG, Emani S, Fay M, Pohl G, Wintle M, Yang E, Oglesby A.
Curr Med Res Opin. 2007 Sep;23(9):2157-69. Review.
Impact of comorbid depression or anxiety on patterns of treatment and economic outcomes among patients with diabetic peripheral neuropathic pain.
Boulanger L, Zhao Y, Foster TS, Fraser K, Bledsoe SL, Russell MW.
Curr Med Res Opin. 2009 Jul;25(7):1763-73.
Treatment patterns and resource use among patients with comorbid diabetes mellitus and major depressive disorder.
Le TK, Curtis B, Kahle-Wrobleski K, Johnston J, Haldane D, Melfi C.
J Med Econ. 2011;14(4):440-7. Epub 2011 Jun 3.
Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.
Laliberté F, Bookhart BK, Vekeman F, Corral M, Duh MS, Bailey RA, Piech CT, Lefebvre P.
J Manag Care Pharm. 2009 May;15(4):312-22.
Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
Pawaskar MD, Camacho FT, Anderson RT, Cobden D, Joshi AV, Balkrishnan R.
Clin Ther. 2007;29 Spec No:1294-305.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on